Skip to main content
OpenTrials
Completed

NCT Number: NCT01789372

Effects of Mediyoga in Patients With Paroxysmal Atrial Fibrillation

The purpose of this study is to determinate if mediyoga has effects in quality of life, heart rate variability, blood pressure , heart rate in patients with paroxysmal atrial fibrillation (PAF).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Paroxysmal Atrial Fibrillation Arrhythmias, Cardiac Atrial Fibrillation Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Sex eligibility

All sexes

Study type

Observational

Primary location

Danderyds hospital

Stockholm, 182 88, Sweden

About this study

This is randomized prospective pilot study. Eighty patients from Danderyd hospital, Stockholm, Sweden were randomized to either mediyoga group or control group. The mediyoga group were completing yoga for one hour, once a week for 12 weeks together with usual treatment. The controlgroup had only usual treatment.The usual treatment consists of pharmaceutical, cardio version and ablation. Quality of life ( SF-36, EQ-5d), blood pressure, heart rate and 24-hours ekokardiografi were measured at baseline and after twelve weeks.A follow up after six months was accomplished with SF-36 and EQ-5d, bloodpressure and heart rate.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of PAF

Exclusion criteria

  • The exclusions criteria were multiple concurrent medical conditions and/or cognitive dysfunction (in the diagnosis of e.g. mental illness), considered not to be able to carry out yoga owing to ability to move and those who have difficulties to understand the Swedish language.

Treatment and study plan

Primary outcomes

  1. Quality of life

    Time frame: Change from baseline in SF-36 after 12 weeks.Change from baseline in SF-36 after six months.

  2. Quality of life

    Time frame: Change from baseline in SF-36 after 12 weeks.Change from baseline in EQ-5D after six month

Secondary outcomes

  1. Blood pressure

    Time frame: Change from baseline in blood pressure after 12 weeks. Change from baseline in blood pressure after six months

  2. heart rate

    Time frame: Change from baseline in heart rate after 12 weeks.Change from baseline in heart rate after six months.

  3. Heart variability

    Time frame: Change from baseline in heart variability after 12 weeks.Change from baseline in heart variability after six months.

Sponsors and collaborators

Lead sponsor

Danderyd Hospital

Other

Registry information

Important dates

Study start
2009
Primary completion
2012
Study completion
2012
First posted
Feb 12, 2013
Registry last updated
Feb 12, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.